Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833586 | 0.82 | PARP1 (0.35) | PARP1PLA2G10PLA2G5SIGMAR1 | |
| SCHEMBL17152994 | 0.82 | PLA2G10 (0.35) | PARP1PLA2G10PLA2G5SIGMAR1 | |
| SCHEMBL28973166 | 0.79 | GRM2 (0.34) | PARP1PLA2G10PLA2G5 | |
| SCHEMBL17153120 | 0.79 | PLA2G10 (0.33) | PARP1PLA2G10PLA2G5 | |
| SCHEMBL8894875 | 0.77 | ZDHHC9 (0.40) | PARP1PLA2G10PLA2G5CA1CA2 | |
| SCHEMBL31315395 | 0.75 | PLA2G10 (0.36) | PARP1PLA2G10PLA2G5 | |
| SCHEMBL9098808 | 0.72 | PARP1 (0.50) | PARP1 | |
| SCHEMBL1149942 | 0.72 | PARP1 (0.50) | PARP1 | |
| SCHEMBL30426265 | 0.72 | KDM4E (0.37) | — | |
| SCHEMBL7116763 | 0.72 | SLC6A1 (0.44) | CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268402-B2 | Fullerene film and fullerene polymer both produced from fullerene derivative and processes for producing these | FRONTIER CARBON CORPORATION (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20100317767-A1 | FULLERENE FILM AND FULLERENE POLYMER BOTH PRODUCED FROM FULLERENE DERIVATIVE AND PROCESSES FOR PRODUCING THESE | FRONTIER CARBON CORPORATION (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2098549-A1 | FULLERENE FILM USING FULLERENE DERIVATIVE AS RAW MATERIAL, FULLERENE POLYMER AND THEIR PRODUCTION METHODS | Frontier Carbon Corporation (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317767-A1 | FULLERENE FILM AND FULLERENE POLYMER BOTH PRODUCED FROM FULLERENE DERIVATIVE AND PROCESSES FOR PRODUCING THESE | RNF168, FTO, MGMT | PARP1 924/4885PLA2G10 1057/4885PLA2G5 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.